Gilead Sciences Q1 Revenues Up 36% Driven By Antiviral Franchise
Gilead Sciences posted a net income of $852m for the first quarter 2010, compared to $586.57m for the prior year period. Income from operations was $1.16bn, compared to
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
Rezaltas is a combination drug featuring the Daiichi Sankyo-developed olmesartan medoxomil (Olmetec), a high-affinity ARB (angiotensin receptor blocker) and azelnidipine (Calblock), a long-acting CCB (calcium channel blocker) that